• Publications
  • Influence
JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?
Activating tyrosine kinase (TK) mutations disrupt cellular proliferation and survival pathways and are increasingly recognized as a fundamental cause of human cancers. Until very recently, the onlyExpand
  • 52
  • 2
A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome.
BACKGROUND AND OBJECTIVES Acquired alpha thalassemia (hemoglobin H (HbH) disease) is a rare complication of neoplastic chronic myeloid disorders, especially myelodysplastic syndrome. Acquired HbH hasExpand
  • 9
Are we overtreating intraductal papillomas?
BACKGROUND The management of intraductal papillomas (IDPs) diagnosed on core needle biopsy (CNB) remains controversial regarding whether excision is required. We evaluated whether excision of IDPsExpand
  • 2
Comparison of Nodal Metastasis Between BRCA Mutation Carriers and Non-BRCA Mutation Carriers with Breast Cancer
AbstractObjective This study evaluates whether nodal status differs between breast cancer patients with BRCA mutations and those confirmed not to harbor mutations.MethodsA prospective databaseExpand
  • 5
A Novel 5′ ATRX Point Mutation with Splicing Consequences in Chronic Myelomonocytic Leukemia with Immune Dysregulation and Acquired Alpha Thalassemia.
BACKGROUND: Acquired hemoglobin disorders including α thalassemia (hemoglobin H (HbH) disease) can complicate neoplastic myeloid disorders, especially myelodysplastic syndrome (MDS). Acquired αExpand
  • 1
Erratum
Figure 2. Putative JAK2 structure, based on homology with other tyrosine kinases such as fibroblast growth factor, where the crystal structure has been solved. This ribbon diagram displays the activeExpand